Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer Feb 23, 2017
Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium Jan 20, 2017
Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update Nov 7, 2016
Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 – A Cancer Cell Specific Anticancer Agent Oct 31, 2016
Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of Docetaxel for the Targeted Treatment of Solid Tumors Oct 26, 2016
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress Oct 10, 2016
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress Oct 4, 2016
Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer Sep 12, 2016
